



February 6, 2021

The Manager- Listing **BSE Limited** Corporate Relationship Dept., 5th Floor, New Trading Ring Rotunda Building, P J Towers, Dalal Street, Fort, Mumbai - 400001

The Manager- Listing National Stock Exchange of India Limited Exchange plaza, 5th Floor, Plot No. C/1, G Block Bandra –Kurla Complex, Bandra (E), Mumbai - 400051

Dear Sir(s),

Sub: AstraZeneca Pharma India Limited receives Import and Market Permission in Form CT-20 (Subsequent New Drug Approval) from the Drugs Controller General of India for Dapagliflozin Tablets 10mg

This is to inform that AstraZeneca Pharma India Limited has received Import and Market Permission in Form CT-20 (**Subsequent New Drug Approval**) from the Drugs Controller General of India for Dapagliflozin Tablets 10mg.

Dapagliflozin Tablets 10mg is now approved for additional indication: For the treatment of patients of Chronic Kidney Disease up to Stage III (eGFR of greater than or equal to 30ml/min/1.73m²).

The receipt of this permission paves way for the launch of Dapagliflozin Tablets 10mg into a new disease area to Nephrologists in India, subject to the receipt of related statutory approvals and licenses.

We request you to kindly take the same on record.

For AstraZeneca Pharma India Limited

Pratap Rudra Company Secretary & Legal Counsel

CORPORATE & REGD. OFFICE AstraZeneca Pharma India Ltd. P. B. No. 4525, Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore - 560 045, INDIA TEL : +91 80 6774 8000 FAX : +91 80 6774 8857 CIN : L24231KA1979PLC003563 WEB : www.astrazeneca.com/india FACTORY 12th Mile on Bellary Road Venkatala, Kattigenahalli Village Yelahanka Bangalore - 560 063 INDIA TEL : +91 80 6774 9000

FAX : +91 80 2846 2208 +91 80 6774 9628